Welcome to our dedicated page for Achilles Therapeutics Plc news (Ticker: ACHL), a resource for investors and traders seeking the latest updates and insights on Achilles Therapeutics Plc stock.
Achilles Therapeutics plc (ACHL) is a clinical-stage biopharmaceutical company that has focused on AI-powered precision T cell therapies targeting clonal neoantigens in solid tumors. News about Achilles provides insight into how the company has developed and adjusted its programs, platforms, collaborations, and corporate structure over time.
Company announcements have covered clinical updates from its CHIRON and THETIS Phase I/IIa trials in advanced non-small cell lung cancer and recurrent or metastatic melanoma, including data on clonal neoantigen-reactive T cells (cNeT), enhanced host conditioning, and the performance of its VELOS manufacturing process. Releases have also described translational science findings related to tumor evolution, immune evasion, and neoantigen selection using the PELEUS bioinformatics platform.
Investors and researchers following ACHL can find news on strategic collaborations, such as the research collaboration with Arcturus Therapeutics to explore second-generation personalized mRNA cancer vaccines based on clonal neoantigens. Additional updates have detailed the sale of technology assets and data from the TRACERx NSCLC study and the Material Acquisition Platform (MAP) to AstraZeneca, marking significant changes in the company’s asset base and focus.
Recent corporate news has included strategic reviews, the discontinuation of the TIL-based cNeT program, closure of the CHIRON and THETIS trials, workforce and governance changes, and steps related to Nasdaq listing status. These include Nasdaq deficiency notices, a transfer to the Nasdaq Capital Market, and later, the company’s stated intention to voluntarily delist its ADSs and pursue a members’ voluntary liquidation. This news page aggregates such releases so readers can follow the evolution of Achilles Therapeutics’ clinical efforts, partnerships, financial updates, and planned wind-down.
Achilles Therapeutics (NASDAQ: ACHL) leads a consortium awarded a €4 million ($4.2 million) grant from Horizon Europe to develop a first-in-class smart bioprocessing manufacturing platform for personalized cell therapies. This initiative aims to enhance manufacturing processes by incorporating advanced sensors and machine-learning controls. Of the total funding, approximately €1.4 million ($1.5 million) will go to Achilles. The project, named SMARTER, involves collaboration with leading institutions to advance cancer immunotherapy.
Achilles Therapeutics (NASDAQ: ACHL) announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board, effective July 1, 2022. Taylor has over 25 years of experience in pharmaceutical and biotech deal-making, previously at Sosei Heptares and GSK. His focus will be on enhancing strategic partnerships for precision T cell therapies targeting solid tumors. Dr. Yee is a respected leader in immuno-oncology, contributing to the advancement of adoptive cellular therapy at MD Anderson Cancer Center.
Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, has won the PING Innovation Award for its advancements in precision T cell therapies targeting clonal neoantigens. This award recognizes organizations making a significant impact in pharmaceuticals and life sciences. CEO Iraj Ali highlighted the company's commitment to developing individualized cancer treatments using AI-powered bioinformatics and unique patient data. Achilles is currently conducting two Phase I/IIa trials for advanced non-small cell lung cancer and melanoma, showcasing its innovative approach to cancer treatment.
Achilles Therapeutics (ACHL) announced key developments in its clinical trials and business operations as of May 10, 2022. They dosed the first patient in the CHIRON trial for advanced non-small cell lung cancer (NSCLC) with a higher-dose cNeT therapy and initiated enrollment for THETIS Cohort B, targeting metastatic melanoma. The company reported a robust cash balance of $236.9 million, sufficient to maintain operations into the second half of 2024. R&D expenses rose to $13 million, reflecting increased trial activities, while the net loss for Q1 2022 stood at $17.4 million.
Achilles Therapeutics (NASDAQ: ACHL) has announced significant progress in its clinical trials. The first patient received a personalized clonal neoantigen-reactive T cell (cNeT) in the CHIRON trial for advanced non-small cell lung cancer (NSCLC). Following a positive review by the Independent Data Safety Monitoring Committee, enrollment for THETIS Cohort B has also begun, testing cNeT with a PD-1 inhibitor for metastatic melanoma. Results from both trials are anticipated in the second half of 2022, highlighting the company's commitment to treating difficult cancers.
Achilles Therapeutics (NASDAQ: ACHL) announced the appointment of Bernhard Ehmer as a Non-Executive Director, enhancing the Board with his extensive experience in R&D and regulatory affairs. Previously, Ehmer held leadership roles in several biotech firms, including CEO of Biotest AG. The company also reported the resignation of Derek DiRocco from the Board on May 3, 2022. This transition comes as Achilles focuses on advancing its precision T cell therapies targeting cancer, supported by its proprietary PELEUS™ bioinformatics platform.
Achilles Therapeutics (NASDAQ: ACHL) announced its participation in two key conferences this May. The Bank of America 2022 Healthcare Conference will be held from May 9-13 in Las Vegas, where CEO Iraj Ali will speak on May 11 at 4:00 PM PT. Additionally, at the H.C. Wainwright Global Investment Conference from May 23-26 in Miami, VP Lee Stern will present on May 24 at 5:00 PM ET. Achilles focuses on developing precision T cell therapies for solid tumors, utilizing its proprietary PELEUS™ bioinformatics platform.
Achilles Therapeutics (NASDAQ: ACHL) announced a significant expansion in clinical manufacturing capabilities in the UK and US. The UK facility at the Cell & Gene Therapy Catapult has achieved GMP certification and will support ongoing Phase I/IIa trials with a new capacity for 600 doses of personalized cNeT therapies. The US partnership with the Center for Breakthrough Medicines will enhance supply chain operations with up to 200 doses. This expansion is expected to strengthen clinical operations and support future growth in treating advanced cancers.
Achilles Therapeutics (NASDAQ: ACHL) announced its participation in key conferences throughout April 2022 to discuss its innovative T cell therapies for solid tumors. On April 5, CEO Iraj Ali will join a panel at the Accelerating Bio-Innovation 2022 in Cambridge. Subsequently, he will present at the Needham Virtual Healthcare Conference on April 12, and attend the Kempen Life Sciences Conference on April 20 for investor meetings. A significant KOL webcast on April 14 will feature Professor Charles Swanton discussing the implications of the TRACERx study for personalized cancer treatment.
Achilles Therapeutics plc (NASDAQ: ACHL) announces a KOL webcast scheduled for April 14, 2022, at 10:30 AM ET. The event will feature Professor Charles Swanton, who will discuss the TRACERx study's role in identifying clonal neoantigens for personalized T cell therapies. The TRACERx study, with over 3,200 tumor samples from 800 lung cancer patients, is crucial for validating Achilles’ AI-powered PELEUS platform. The webcast will include presentations from key experts and a Q&A session moderated by Dr. Joseph Catanzaro.